{
  "docId": "019de072-1a15-7369-8097-68fb5b1d5017",
  "docSlug": "de0c004f3134112f269aa7aa17f1a1f3",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 39 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 39,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a three-column layout to categorize performance metrics and operational highlights.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-1a15-7369-8097-68fb5b1d5017/6",
  "deckHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017",
  "deckJsonHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017.json",
  "deckAnchorHref": "/decks/019de072-1a15-7369-8097-68fb5b1d5017#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.94,
        "x": 0.03,
        "y": 0.8
      },
      "kind": "callout",
      "text": "FY 2021: Total Revenue $37.4bn (+38%) | Core EPS of $5.29 (+37%)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66250041-2ff3-4b71-9bae-9cca7bd9cc1a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.03,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "Absolute values at actual exchange rates; changes at constant exchange rates (CER)...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72f15271-a4ae-407b-84af-8dea3a224c35",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.35,
        "y": 0.23
      },
      "kind": "list",
      "text": "Broad-based performance: Delivering value to patients. Oncology $13.7bn (+17%), BioPharmaceuticals (CVRM $8.0bn, Resp & Imm $6.0bn, Other $2.5bn, COVID-19 $4.1bn), Rare Disease $3.1bn (+9%).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55c738de-6ba6-4e4d-8e48-cc86f4c7275e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.03,
        "y": 0.23
      },
      "kind": "list",
      "text": "Robust growth: Exceeded FY 2021 revenue guidance. Total Revenue $37.4bn (+38%), $33.4bn (+23%) excluding Vaxzevria, $35.2bn (+30%) including Q4 Vaxzevria. Core EPS $5.29 (+37%).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2194ada-7554-4d10-9e9c-558a288da339",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.67,
        "y": 0.23
      },
      "kind": "list",
      "text": "Science-led innovation: Strong Q4 2021 performance. Tezspire US approval, Evusheld US EUA, Lynparza US Priority Review, Saphnelo EU CHMP recommendation, Ultomiris US Priority Review.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea7046b0-0a04-4c37-a6ab-ca7acb55f5e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Continuing to deliver on our strategic objectives",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "deebc3e1-bc7c-4a6e-8818-b1109d89a1b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Full year and Q4 2021: key updates",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d850cea3-7381-4951-afbf-37ecdcbc38a4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "action-titles",
      "slug": null,
      "matchId": "e0802c50-54e4-46ac-a7e2-4df5e7d1146e",
      "evidence": "The slide uses a descriptive headline followed by a strategic action-oriented sub-headline.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 6,
      "beatId": "1ebb2b41-d88f-40eb-aa61-f0b44beb2217",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The presentation highlights the company's strong growth and pipeline, addressing the need for innovation.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 6,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "cda2daa8-5b26-4954-80bc-b7864ff91f9b",
      "evidence": "The presentation links growth to life-cycle management, pipeline, and strategic business development.",
      "position": 0,
      "objective": "How will AstraZeneca continue to drive growth?",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}